Investor News no. 04/2019

To: NASDAQ Copenhagen A/S                                                  

Copenhagen, Denmark, 6 August 2019

Veloxis to Host Conference Call Following Release of Interim Financial Report for the Period 1 January to 30 June 2019

 

Veloxis Pharmaceuticals A/S (NASDAQ: VELO) will release its Interim Report for the second quarter 2019 on Thursday, August 8, 2019. 

In connection with the release, Veloxis’s Executive Management will host a conference call to discuss the financial results on Friday, August 9, 2019 at 4:00 p.m. CET (Denmark); 3:00 p.m. GST (London); and 10:00 a.m. EST (New York).

 

To access the live conference call, please dial one of the following numbers:

+1 917 720 0178 (USA)

+45 32 72 75 18 (Denmark)

+44 (0) 203 009 5710 (UK)

Confirmation Code: 1794852

Following the conference call, a recording will be available on the Company’s website: http://www.veloxis.com.

 

For more information, please contact:

 Craig A. Collard    Ira Duarte
 President & CEO  CFO
 Phone: + 1 919 591 3090  Phone: +1 919 591 3090
 Email: cac@veloxis.com  Email: idu@veloxis.com

 

About Veloxis Pharmaceuticals

Veloxis Pharmaceuticals A/S is a commercial-stage specialty pharmaceutical company committed to improving the lives of transplant patients.  A Danish company, Veloxis Pharmaceuticals A/S operates in the U.S. through Veloxis Pharmaceuticals Inc., a wholly-owned subsidiary headquartered in Cary, North Carolina, USA.  Veloxis has successfully developed Envarsus XR (tacrolimus extended-release tablets) based upon the company's unique and patented delivery technology, MeltDose®, which is designed to enhance the absorption and bioavailability of select orally administered drugs. The company is focused on the direct commercialization of Envarsus XR in the U.S., expansion of partnerships for markets around the world, and acquisition of assets utilized in transplant patients and by adjacent medical specialties. Veloxis is listed on the NASDAQ OMX Copenhagen under the trading symbol OMX: VELO.  

For further information, please visit www.veloxis.com.

 

Attachment